Regeneron Pharmaceuticals, Inc. patent applications published on July 25th, 2024
Summary of the patent applications from Regeneron Pharmaceuticals, Inc. on July 25th, 2024
1. **Summary**: Regeneron Pharmaceuticals, Inc. has recently filed patents related to innovative technologies in biometric authentication, protein characterization, and stroke treatment. These patents introduce novel methods and approaches to enhance security, study protein interactions, and manage stroke risks effectively.
2. **Key Points of Patents**:
* Biometric Authentication System:
* Analyzes biometric movements from static and mobile devices.
* Validates user identity through static and mobile attributes.
* Enhances security and authentication processes.
* Protein Characterization Technology:
* Utilizes native immunoprecipitation and mass spectrometry.
* Identifies and quantifies antibody pairing products.
* Improves understanding of protein interactions.
* Stroke Treatment Using GBE1 Inhibitor:
* Administers GBE1 inhibitor to treat stroke patients.
* Targets specific enzyme to prevent stroke risks.
* Offers new approach to stroke management.
3. **Notable Applications**:
* Biometric Authentication System:
* Secure authentication in banking, healthcare, and government services.
* Protein Characterization Technology:
* Used in biotechnology, pharmaceuticals, and medical research.
* Stroke Treatment Using GBE1 Inhibitor:
* Treatment of stroke patients and prevention in high-risk individuals.
These patents showcase Regeneron Pharmaceuticals, Inc.'s commitment to innovation in diverse fields, offering potential advancements in security, healthcare, and research.
Contents
- 1 Patent applications for Regeneron Pharmaceuticals, Inc. on July 25th, 2024
- 1.1 METHODS OF MODELING LIQUID PROTEIN COMPOSITION STABILITY (18420955)
- 1.2 METHODS OF TREATING CANCER PAIN BY ADMINISTERING A PD-1 INHIBITOR (18438746)
- 1.3 FGFR3 BINDING MOLECULES AND METHODS OF USE THEREOF (18412280)
- 1.4 Compositions and Methods for Enhancing Body Weight and Lean Muscle Mass Using Antagonists Against Leptin Receptor, GDF8 and Activin A (17415589)
- 1.5 Treatment Of Stroke With 1,4-Alpha-Glucan-Branching Enzyme (GBE1) Inhibitors (18421326)
- 1.6 MASS SPECTROMETRY-BASED CHARACTERIZATION OF ANTIBODIES CO-EXPRESSED IN VIVO (18422188)
- 1.7 SYSTEMS AND METHODS FOR MOBILE AND STATIC BIOMETRIC MOVEMENT TRACKING (18420090)
Patent applications for Regeneron Pharmaceuticals, Inc. on July 25th, 2024
METHODS OF MODELING LIQUID PROTEIN COMPOSITION STABILITY (18420955)
Main Inventor
Douglas E. KAMEN
METHODS OF TREATING CANCER PAIN BY ADMINISTERING A PD-1 INHIBITOR (18438746)
Main Inventor
Chieh-I Chen
FGFR3 BINDING MOLECULES AND METHODS OF USE THEREOF (18412280)
Main Inventor
Yan YANG
Compositions and Methods for Enhancing Body Weight and Lean Muscle Mass Using Antagonists Against Leptin Receptor, GDF8 and Activin A (17415589)
Main Inventor
Judith Altarejos
Treatment Of Stroke With 1,4-Alpha-Glucan-Branching Enzyme (GBE1) Inhibitors (18421326)
Main Inventor
Neelroop Parikshak
MASS SPECTROMETRY-BASED CHARACTERIZATION OF ANTIBODIES CO-EXPRESSED IN VIVO (18422188)
Main Inventor
Yuetian Yan
SYSTEMS AND METHODS FOR MOBILE AND STATIC BIOMETRIC MOVEMENT TRACKING (18420090)
Main Inventor
Matthew F. WIPPERMAN
